Additional Data and Trials-in-Progress Across Daiichi Sankyo’s DXd ADC Portfolio at ASCO Additional sub-analyses from the TROPION-Lung02 phase 1b trial (#8617) evaluating datopotamab deruxtecan ...

Susan Galbraith, Ph.D. (AstraZeneca) AZ and Daiichi have not yet unveiled their front-line strategy for Enhertu in HER2-low breast cancer. But AZ’s Galbraith hinted at the possibility of a more ...

Daiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCO. Late-breaking data from DESTINY-Breast09 and DESTINY-Gastric04 phase 3 ...

Daiichi Sankyo (TSE: 4568) ... June 3, 2025 from 8:00 to 9:15 am JST. Executives from Daiichi Sankyo will provide an overview of the ASCO research data and address questions.